Literature DB >> 19756528

Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies.

Olivier Blin1, Christine Audebert, Séverine Pitel, Arthur Kaladjian, Catherine Casse-Perrot, Mohammed Zaim, Joelle Micallef, Jacky Tisne-Versailles, Pierre Sokoloff, Philippe Chopin, Marc Marien.   

Abstract

RATIONALE: Dimethylaminoethanol pyroglutamate (DMAE p-Glu) is a compound resulting from the reaction between dimethylaminoethanol (an indirect precursor of acetylcholine) and pyroglutamic acid (a cyclic derivative of glutamic acid having procholinergic properties and promnesic effects in both animals and man).
OBJECTIVES: The present study undertook preclinical and clinical evaluations to test a potential therapeutic utility for DMAE p-Glu in cognitive impairments related to central cholinergic deficit.
MATERIALS AND METHODS: In preclinical study, DMAE p-Glu was studied in rats by intracerebral microdialysis in conscious freely moving animals, on performance of rats in the Morris water maze test of spatial memory, and on the deficit in passive avoidance behavior induced by scopolamine. The clinical study examined the effect of DMAE p-Glu on cognitive deficits induced by an intravenous injection of scopolamine in healthy young male subjects.
RESULTS: In rat experiments, DMAE p-Glu increased the extracellular levels of choline and acetylcholine in the medial prefrontal cortex, as assessed by intracerebral microdialysis, improved performance in a test of spatial memory, and reduced scopolamine-induced memory deficit in passive avoidance behavior. Clinical study results show that scopolamine induced a memory deficit and that DMAE p-Glu produced a significant positive effect on scores in the Buschke test, as well as a slight but significant difference on choice reaction time.
CONCLUSION: These results indicate that DMAE p-Glu reduces the deleterious effect of scopolamine on long-term memory in healthy volunteers and suggest that DMAE p-Glu might be effective in reducing memory deficits in patients with cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756528     DOI: 10.1007/s00213-009-1648-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  38 in total

Review 1.  Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents.

Authors:  M Sarter; J P Bruno
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  TRH attenuates scopolamine-induced memory impairment in humans.

Authors:  S E Molchan; A M Mellow; B A Lawlor; H J Weingartner; R M Cohen; M R Cohen; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Early clinical testing of cognition enhancers: prediction of efficacy.

Authors:  S T Hall; A Puech; K Schaffler; K Wesnes; E R Gamzu
Journal:  Pharmacopsychiatry       Date:  1990-02       Impact factor: 5.788

4.  Space motion sickness medications: interference with biomedical parameters.

Authors:  J Vernikos-Danellis; C M Winget; C S Leach; L S Rosenblatt; J Lyman; J R Beljan
Journal:  Acta Astronaut       Date:  1977       Impact factor: 2.413

5.  Amnesic effects of scopolamine.

Authors:  S D Glick; B Zimmerberg
Journal:  Behav Biol       Date:  1972-04

Review 6.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

7.  Alpha2-adrenoceptor modulation of cortical acetylcholine release in vivo.

Authors:  S Tellez; F Colpaert; M Marien
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

8.  Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans.

Authors:  R Martinez; S E Molchan; B A Lawlor; K Thompson; H Martinson; G Latham; H Weingartner; T Sunderland
Journal:  Biol Psychiatry       Date:  1997-01-01       Impact factor: 13.382

9.  Pyroglutamic acid administration modifies the electrocorticogram and increases the release of acetylcholine and GABA from the guinea-pig cerebral cortex.

Authors:  T Antonelli; V Carlà; L Lambertini; F Moroni; C Bianchi
Journal:  Pharmacol Res Commun       Date:  1984-02

10.  Memory and cognitive function in man: does the cholinergic system have a specific role?

Authors:  D A Drachman
Journal:  Neurology       Date:  1977-08       Impact factor: 9.910

View more
  5 in total

Review 1.  Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions.

Authors:  Francine Johansson Azeredo; Teresa Dalla Costa; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

2.  An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

Authors:  Anne Catrien Baakman; Ricardo Alvarez-Jimenez; Robert Rissmann; Erica S Klaassen; Jasper Stevens; Sebastiaan C Goulooze; Jeroen C G den Burger; Eleonora L Swart; Joop M A van Gerven; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2017-04-08       Impact factor: 4.335

3.  The glutathione cycle shapes synaptic glutamate activity.

Authors:  Thomas W Sedlak; Bindu D Paul; Gregory M Parker; Lynda D Hester; Adele M Snowman; Yu Taniguchi; Atsushi Kamiya; Solomon H Snyder; Akira Sawa
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-28       Impact factor: 11.205

4.  The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors.

Authors:  Martin Lochner; Andrew J Thompson
Journal:  Neuropharmacology       Date:  2016-04-22       Impact factor: 5.250

Review 5.  Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs.

Authors:  Matěj Malík; Pavel Tlustoš
Journal:  Nutrients       Date:  2022-08-17       Impact factor: 6.706

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.